Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy.
Tao-Han LeeJia-Jin ChenChao-Yi WuChih-Wei YangHuang-Yu YangPublished in: Diagnostics (Basel, Switzerland) (2021)
The relationship between hyperuricemia, gout, and renal disease has been investigated for several years. From the beginning, kidney disease has been considered a complication of gout; however, the viewpoints changed, claiming that hypertension and elevated uric acid (UA) levels are caused by decreased urate excretion in patients with renal impairment. To date, several examples of evidence support the role of hyperuricemia in cardiovascular or renal diseases. Several mechanisms have been identified that explain the relationship between hyperuricemia and chronic kidney disease, including the crystal effect, renin-angiotensin-aldosterone system activation, nitric oxide synthesis inhibition, and intracellular oxidative stress stimulation, and urate-lowering therapy (ULT) has been proven to reduce renal disease progression in the past few years. In this comprehensive review, the source and physiology of UA are introduced, and the mechanisms that explain the reciprocal relationship between hyperuricemia and kidney disease are reviewed. Lastly, current evidence supporting the use of ULT to postpone renal disease progression in patients with hyperuricemia and gout are summarized.
Keyphrases
- uric acid
- metabolic syndrome
- chronic kidney disease
- nitric oxide
- oxidative stress
- end stage renal disease
- blood pressure
- angiotensin ii
- angiotensin converting enzyme
- hydrogen peroxide
- cell therapy
- reactive oxygen species
- ischemia reperfusion injury
- bone marrow
- heat stress
- atomic force microscopy
- replacement therapy
- smoking cessation